Alopecia areata is a chronic immune-mediated autoimmune disorder targeting hair follicles and causing sudden, nonscarring patchy hair loss. The condition often follows a relapsing course, though spontaneous regrowth can occur.
AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.
Nektar said extended rezpeg treatment promoted greater hair growth in severe alopecia areata and reported durable 52-week efficacy for rezpegaldesleukin in atopic dermatitis. The company said it has FDA alignment on Phase 3 design and is targeting a BLA submission by 2029.
AbbVie said Skyrizi and Rinvoq generated $26.0 billion in 2025 sales and are expected to exceed $31 billion in 2026. The company said the two immunology drugs continue to offset Humira erosion and drive top-line growth.
HCW Biologics regained compliance with Nasdaq listing rules and completed a follow-on offering priced at $0.6055 per unit to raise approximately $1.5 million for clinical development of immunotherapies targeting chronic inflammation.
Nektar Therapeutics is advancing its immunology pipeline with plans to initiate Phase 3 trials for REZPEG in atopic dermatitis next quarter, following positive Phase 2b results. The company recently completed a large equity raise to support its regulatory T cell-focused programs.
Recent studies examine safety profiles of GLP-1 receptor agonists, finding increased risk for nonscarring hair loss but improved survival in patients with brain metastases and type 2 diabetes.
The alopecia areata treatment market is projected to grow significantly through 2036, driven by rising prevalence and the anticipated launch of emerging therapies including JAK inhibitors and novel drug classes targeting immune pathways.
Nektar Therapeutics completed a $460 million public offering on February 13, 2026, selling 7.6 million shares of common stock and pre-funded warrants. The clinical-stage biotechnology company is developing immunotherapy treatments for autoimmune diseases.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07533006 |
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) |
RECRUITING | PHASE2 |
| NCT07499713 |
Association of Serum VEGF-A and VCAM-1 Levels With Nailfold Capilleroscopic Alterations in Alopecia Areata |
ENROLLING_BY_INVITATION | |
| NCT07459933 |
Topical Methotrexate vs Minoxidil for Localized Alopecia Areata |
NOT_YET_RECRUITING | PHASE4 |
| NCT07454876 |
Association of TLR7 Gene rs3853839 Polymorphism With Disease Severity in Alopecia Areata: A Case-Control Study |
COMPLETED | |
| NCT07453238 |
Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata |
NOT_YET_RECRUITING | PHASE4 |
| NCT07406204 |
Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA) |
NOT_YET_RECRUITING | PHASE4 |
| NCT07336641 |
LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice |
NOT_YET_RECRUITING | |
| NCT07311564 |
A Study of LAD603 in Adults With Alopecia Areata |
RECRUITING | PHASE2 |
| NCT07250997 |
PALLAS Laser for Skin Diseases |
RECRUITING | NA |
| NCT07243977 |
Comparison of Microneedling Along With Topical Vitamin D3 Versus Microneedling in Alopecia Areata |
ACTIVE_NOT_RECRUITING | NA |
